Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biogeneric TNF-alpha inhibitors for the treatment of rheumatoid arthritis will become the first $1 billion biogeneric class across the United States and Europe in 2014. U.S. biogeneric TNF-alpha inhibitors will experience high growth following their entry in 2012 before peaking in 2013 at nearly $800 million in the United States alone. European biogeneric TNF-alpha inhibitors, which will begin hitting the market in 2014, will generate nearly as much sales in rheumatoid arthritis as their U.S. counterparts in 2016, with nearly $600 million in annual sales.

According to the new special report entitled Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion, biogeneric Herceptin may prove to be the hidden gem for biogeneric manufacturers seeking less crowded markets.

"Our forecast shows that biogeneric Herceptin will peak at nearly $600 million in annual sales at the end of our forecast period; no other key biogeneric drugs will post sales as high, except the TNF-alpha inhibitor class," said Andrew Merseth, analyst at Decision Resources. "Although no biogenerics company has announced biogeneric Herceptin development plans, surveyed solid-tumor oncologists make it clear that this agent would enjoy rapid adoption, allowing biogenerics manufacturers to quickly capture a sizable portion of branded Herceptin sales."

About Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion

Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion covers 13 key biologic brands used in 8 indications and includes more primary research than any other report produced by Decision Resources. It includes surveys of 317 specialists from the United States, France, and Germany, as well as 40 U.S. HMO pharmacy directors. The report includes a 10-year annualized forecast for the 13 key brands and for their biogeneric competition and provides a framework for forecasting other biogenerics.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

California's Pay for Performance Breaks Ground With New Program Components

View Now